Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a combined financing comprising a SEK 172 million equity private placement and a SEK 290 million debt financing.
Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Lorin Arabi and Isabell Bitar (Capital Markets and Public M&A) and of Albert Wållgren, Arvid Weimers and Ida Redander (Banking and finance).
